Cancer Cell 'Under Review': What Each Status Means and Realistic Timelines

Cancer Cell's in-house editors hold PhDs in relevant fields. They aren't generalists scanning abstracts; they're trained scientists who read your paper carefully and evaluate it against a specific editorial bar. That bar is high.

During the desk screen, editors are looking for several things at once:

• A clear conceptual advance in cancer biology. Not just new data, but a finding that shifts how we understand a tumor type, a signaling pathway, a resistance mechanism, or a therapeutic approach. Incremental work, no matter how clean, won't make it past the desk.

• Mechanistic depth. Cancer Cell expects you've gone beyond correlation. If you're reporting that gene X is associated with outcome Y, you'd better have functional data showing how and why.

• Multi-platform validation. Cell lines alone won't cut it. Editors want to see findings confirmed across patient samples, animal models, organoids, or at least orthogonal experimental systems. The more independent lines of evidence converging on the same conclusion, the stronger your case.

• Clinical relevance or therapeutic implication. This doesn't mean you need a clinical trial, but your story should connect back to human disease in a meaningful way. Pure basic science without a clear cancer angle is better suited for Cell or Molecular Cell.

• Completeness. Half-told stories get desk rejected even when the science is excellent. If it feels like there's a missing chapter, the editor won't send it out.

If your manuscript survived all of that, you're in a strong position. Don't underestimate what it means to clear this hurdle.

Once your paper enters "Under Review," the editor selects 2-3 external reviewers with specific expertise in your topic area. Cancer Cell reviewers tend to be established investigators who've published in the journal themselves or in closely related Cell Press journals.

Here's what reviewers are typically evaluating:

Scientific rigor. Are the experiments well-controlled? Are the statistical methods appropriate? Reviewers will scrutinize your supplementary data just as carefully as your main figures, so don't treat supplementary material as a dumping ground for weak experiments.

Novelty relative to existing literature. Reviewers often know the field better than anyone. They'll flag if a similar finding was reported six months ago in a different journal, even if you weren't aware of it. Make sure your literature review is current.

Experimental completeness. Cancer Cell reviewers frequently ask for additional experiments. This isn't unusual and it shouldn't alarm you. The journal's standard is that every major claim needs to be supported by multiple independent lines of evidence. If your paper has five main claims, expect at least a few of them to be probed with requests for additional validation.

Writing and figure quality. Cancer Cell papers are long and data-rich, but they still need to tell a coherent story. Reviewers will comment if your narrative is hard to follow, if figures are poorly organized, or if key data is buried in supplementary files when it should be in the main text.

Translational potential. Even for basic science papers, reviewers consider whether the findings could eventually inform treatment, diagnostics, or patient stratification. This doesn't mean you need to overstate clinical implications, but connecting your work to the bigger picture of cancer care matters here.

Like all Cell Press journals, Cancer Cell uses a "revision before review" option. If you receive this, it means the editor thinks your paper is interesting but not quite ready for external review. They'll outline specific changes they want to see first.

This is genuinely good news. The editor could've desk rejected you. Instead, they're investing time to help shape the manuscript. Think of it as an editorial mentorship moment rather than a soft rejection.

Common reasons for revision-before-review requests at Cancer Cell:

• The mechanistic story isn't complete enough for reviewers to evaluate fairly
• Key controls are missing from central experiments
• The paper's framing doesn't match Cancer Cell's scope (too basic, or too clinical without mechanism)
• Human data is needed to complement mouse models
• The paper is too long or poorly organized, making it hard to assess

When you get this request, respond within the suggested timeline (usually 2-4 weeks for minor adjustments, longer if new experiments are needed). Address every single point the editor raised. If you can't do something they asked for, explain why honestly. Editors respect transparency far more than hand-waving.

Once reviewers submit their reports, the editor synthesizes everything and makes a decision. Here's what you might receive:

Accept. This is vanishingly rare on the first round. I've seen estimates that fewer than 5% of Cancer Cell papers are accepted without any revision. If it happens to you, celebrate loudly.

Minor revision. You're essentially accepted. The editor wants small clarifications, a few additional analyses, or textual changes. You'll typically get 2-4 weeks to turn this around. Don't overthink it; just do what's asked cleanly and quickly.

Major revision. The most common positive outcome. Reviewers want new experiments, additional data analysis, rewritten sections, or expanded discussion. Cancer Cell major revisions often require 2-4 months of additional work. The scope can feel daunting, but remember: the editor wouldn't ask for revisions if they didn't think the paper could ultimately be published.

Reject with option to resubmit. This means the current version doesn't meet the bar, but the editor sees enough promise that a substantially revised version could be reconsidered. This isn't a guaranteed path to acceptance, but it's better than a flat rejection.

Reject. Even after peer review, Cancer Cell rejects a significant fraction of papers. Roughly 40-50% of manuscripts that enter peer review don't make it through. The rejection letter should explain what fell short, and often it'll suggest alternative journals.

If you're lucky enough to get a revision request, here's how to approach it:

1. Read everything twice before reacting. Your first emotional response to reviewer criticism is almost always more negative than warranted. Give yourself a day, then read again with fresh eyes. You'll find that most comments are fair.

1. Build a point-by-point response document. Number every reviewer comment. For each one, provide your response and describe exactly what changed in the manuscript. Reference specific figure numbers, page numbers, and line numbers.

1. Don't argue unless you have strong evidence. If a reviewer asks for a western blot and you think it's unnecessary, you'd better have a compelling reason. "We believe our existing data is sufficient" rarely convinces anyone. If you disagree, provide data or a well-reasoned argument, not just assertions.

1. Do the experiments. Cancer Cell reviewers and editors can tell when you've half-heartedly addressed a concern versus genuinely engaged with it. If they asked for CRISPR validation and you provided only siRNA knockdown, they'll notice.

1. Flag new data clearly. In your revised manuscript, use colored text or margin annotations to show what's new. In your response letter, state explicitly which figures, panels, or text sections were added or modified.

1. Respect the deadline. Cancer Cell typically provides a revision window. If you need more time, ask for an extension early rather than submitting something rushed at the deadline. Editors are generally understanding about reasonable extension requests.

1. Don't add unnecessary new data. Stick to what was asked. If you've generated exciting new findings during the revision period, consider whether they strengthen the current story or belong in a separate paper. Adding unrequested data can bloat the manuscript and raise new questions that delay the process.

Getting rejected from Cancer Cell after peer review isn't a dead end. Your paper has already been validated by one of the most selective editorial teams in oncology. That's worth something, even if it didn't result in acceptance.

Here are strong alternative targets:

Cancer Cell's Cell Press transfer system is worth using. When the editor suggests transferring to Cell Reports or Cell Reports Medicine, your reviewer reports travel with the manuscript. This means you won't start from scratch, and the receiving journal's editors can see that respected reviewers already evaluated your work positively (or identified fixable issues). It saves months compared to a fresh submission elsewhere.

Don't overlook iScience either. It's Cell Press's broad-access journal and it's grown considerably in both quality and visibility. For papers that are scientifically sound but didn't quite reach Cancer Cell's novelty threshold, it can be a reasonable landing spot.

These are typical ranges. Some papers move faster, particularly if the topic is timely and all reviewers respond promptly. Others drag on, especially when reviewer recruitment proves difficult or when the editor decides to seek an additional reviewer after the first round.

Checking your manuscript status obsessively won't make it move faster, but knowing when it's appropriate to contact the editorial office helps.

• 0-3 weeks under review: Don't contact the journal. This is well within the normal range.

• 3-5 weeks: Still normal for Cancer Cell. Be patient.

• 5-7 weeks: You're approaching the upper bound. A brief, polite inquiry is reasonable.

• 7+ weeks: Follow up if you haven't heard anything. Keep your email short and professional.

A good follow-up looks something like this: "Dear Editor, I'm writing to inquire about the status of manuscript CC-D-26-XXXXX, submitted on [date]. I understand the review process takes time and I appreciate your efforts. Any update on expected timeline would be helpful."

Don't send multiple follow-ups in quick succession. One email every 2-3 weeks is the maximum. And whatever you do, don't CC other editors or escalate to the editor-in-chief unless something has gone genuinely wrong (like 4+ months of silence).

Cancer Cell's editors aren't adversaries. They're scientists who want to publish the best cancer biology they can find. If they've sent your paper to review, they're rooting for it to work out. The review process can feel adversarial, especially when you're reading critical comments at midnight, but the goal is to make your paper stronger.

It's also worth noting that Cancer Cell increasingly values reproducibility and data sharing. If you haven't already deposited your sequencing data, proteomics data, or other large datasets in appropriate repositories, do it now. Reviewers will ask, and having everything ready shows that you've thought about the full publication lifecycle.

Finally, if this is your first submission to a Cell Press journal, don't be surprised by the length and detail of the review process. It's more involved than what you'd experience at most society journals. That's part of what makes the journal selective, and it's part of why a Cancer Cell publication carries the weight it does.

• Cancer Cell journal guide
• Cancer Cell submission guide
• Cancer Cell acceptance rate
• Cancer Cell impact factor
• Cancer Discovery vs Cancer Cell
• Cell Press family journals
• Acceptance rates across journals
• Review timelines compared

In our pre-submission review work with manuscripts targeting Cancer Cell, three failure patterns generate the most consistent desk rejections and major revision requests. We find these across manuscripts we've reviewed through our Cancer Cell submission readiness check.

The mechanistic paper with cell-line data but no in vivo endpoint. Cancer Cell holds a high standard for mechanistic evidence: the chain from molecular finding to cancer-relevant phenotype must be demonstrated in a model that reflects the in vivo tumor environment. We observe that papers with strong cell-line mechanistic data but no xenograft, syngeneic, or genetically engineered mouse model data generate major revision requests for in vivo validation in over half of cases. Including at least one in vivo endpoint at initial submission, even if preliminary, substantially improves the revision trajectory.

The multi-omics paper that presents each dataset in parallel rather than showing integrated insight. Cancer Cell increasingly receives multi-omics papers that describe genomic, transcriptomic, and proteomic findings in parallel sections without demonstrating what the integration reveals beyond the individual data types. We find that reviewers specifically ask: "What does the combined analysis show that the individual datasets do not?" SciRev community data for Cancer Cell identifies integration depth as a recurring revision theme on computational submissions. Papers that lead with an integrative finding and use individual datasets as supporting evidence clear this bar; papers that present datasets in parallel generate requests to demonstrate the integrative insight.

The clinical implication that requires two inferential steps from the experimental data. Cancer Cell editors evaluate whether the translational claim is one step from the experimental finding or whether the reader must draw two inferences to reach the clinical conclusion. We observe that papers where the translational claim requires inferring that a mechanism observed in one cancer model applies to human disease, or that a pathway finding might eventually influence treatment decisions, generate desk rejections citing more appropriate scope in specialty journals. Including at least one patient-derived sample, clinical cohort analysis, or direct clinical validation closes this inferential gap.